A groundbreaking trial is underway to assess the effectiveness of a quick “pill-on-a-thread” test in screening individuals with chronic heartburn for early signs of oesophageal cancer.
The BEST4 Screening Trial marks the culmination of over 20 years of research into the capsule sponge test, an innovative diagnostic tool created by Professor Rebecca Fitzgerald, director of the Early Cancer Institute at the University of Cambridge.
The test starts as a swallowable pill that expands into a sponge once ingested. When retrieved via its attached thread, the sponge gathers cells from the oesophagus for laboratory analysis. This method has already proven significantly more effective at detecting Barrett’s oesophagus—a condition that can precede oesophageal cancer—compared to existing diagnostic methods.
Given that chronic heartburn is the primary symptom of Barrett’s oesophagus, the BEST4 Screening Trial aims to recruit 120,000 participants who frequently take heartburn medications. Supported by funding, the study seeks to determine whether the capsule sponge test can improve early detection of Barrett’s oesophagus, help prevent cancer, and reduce mortality as part of a potential national screening program.
“The capsule sponge is revolutionizing the detection of Barrett’s oesophagus and oesophageal cancer,” explains Professor Fitzgerald, one of the trial’s principal investigators. “Early diagnosis can save lives and minimize the need for chemotherapy or major surgery. Thousands have already benefited in previous trials, and we’re now exploring whether this test could be widely implemented for those with heartburn.”
This trial represents a critical step in transforming oesophageal cancer prevention and treatment.
Read the Full Story Here: https://news.cancerresearchuk.org/2024/11/28/best4-capsule-sponge-oesophageal-cancer-screening-trial/
Original Article by Tim Gunn – Cancer Research